Literature DB >> 1301968

Antiphospholipid antibodies differ in aPL cofactor requirement.

L R Sammaritano1, M D Lockshin, A E Gharavi.   

Abstract

Although autoimmune antiphospholipid antibodies (aPL) may require a serum cofactor, beta 2-glycoprotein I (beta 2GPI), for maximal binding in aPL ELISA, it is not known whether cofactor is absolutely required or is merely an enhancing factor for binding, nor is it clear whether aPL bind to cofactor itself, a cofactor-lipid complex, or a phospholipid modified in some way by cofactor. We therefore isolated and purified beta 2GPI and evaluated its relationship to both IgG and IgM aPL binding. aPL derived from different sera appear to have differing requirements for cofactor; the proportion of total binding attributable to cofactor varies from 46% to 95%. aPL do not bind to beta 2GPI in the absence of phospholipid. Enhanced binding to phospholipid is seen if beta 2GPI is provided either before or with the test antibody. Autoimmune aPL bind phospholipid better with human rather than bovine cofactor. The requirement for cofactor is greater for low-avidity aPL as measured in an IgG-human cofactor system. Cofactor requirement alone does not predict the presence or absence of associated clinical complications.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1301968     DOI: 10.1177/096120339200100205

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  13 in total

Review 1.  Association of anticardiolipin antibodies with vascular injury: possible mechanisms.

Authors:  Y S Haviv
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  Antigenic specificities of "antiphospholipid" autoantibodies.

Authors:  R A Roubey
Journal:  Springer Semin Immunopathol       Date:  1994

Review 3.  Anti-beta 2-glycoprotein I antibodies.

Authors:  J Arvieux; J C Bensa; B Roussel; M G Colomb
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

4.  Report of the First French Anticardiolipin Antibodies Standardization Workshop.

Authors:  N Abuaf; O Meyer; S Laperche; N Saab; B Rajoely; A Deschamps; P Laroche; D Pierron; A M Rouquette
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

5.  Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus.

Authors:  P Gargiulo; J Goldberg; B Romani; R Schiaffini; P Ciampalini; W P Faulk; J A McIntyre
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 6.  Antiphospholipid antibodies and the antiphospholipid syndrome.

Authors:  E N Harris; S S Pierangeli
Journal:  Springer Semin Immunopathol       Date:  1994

Review 7.  Cardiolipin, coagulation, co-factors and connective tissue disease.

Authors:  R S Pereira
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

Review 8.  The antiphospholipid syndrome. Diagnosis, management, and pathogenesis.

Authors:  E N Harris
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

9.  Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

Authors:  R Simantov; J M LaSala; S K Lo; A E Gharavi; L R Sammaritano; J E Salmon; R L Silverstein
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

10.  IgG2 subclass restriction of anti-beta 2 glycoprotein 1 antibodies in autoimmune patients.

Authors:  J Arvieux; B Roussel; D Ponard; M G Colomb
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.